Though there was a suggestive trend for 30‐week outcomes favouring SC use (RR 1.50 (95% CI: 0.95–2.34) and 1.54 (95% CI: 0.99–1.64) for clinical remission and response respectively); however, no comparison reached statistical significance, including in subgroup UC and CD comparisons (Table 2 ). 4.
← all excerpts
Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease.
1
—
—